MediciNova Plans To License MS Agent To European And U.S. Drugmakers
This article was originally published in PharmAsia News
Executive Summary
MediciNova plans to license MN-166 (ibudilast) to European and U.S. drugmakers within the year after a Phase II trial in April showed promising results. A novel, orally administered compound being evaluated to treat multiple sclerosis, ibudilast was licensed from Kyorin Pharmaceutical and has been marketed under the name Ketas for the treatment of asthma and cerebrovascular disorders for the past 18 years. In case of a licensing agreement, which could be reached as early as the end of the year, MediciNova and Kyorin will share a one time payment and royalty payments at a 65-35 split. MedicNova expects the drug to grow to ¥120 billion in sales in five years. MediciNova will also release Phase II results for MN-221 (ritodrine) by the end of the year. Licensed from Kissei Pharmaceutical, ritodrine is being evaluated by the company as an asthma treatment. (Click here for more - Japanese language
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.